BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 25428222)

  • 1. Toward optimal therapy for inhibitors in hemophilia.
    Kempton CL; Meeks SL
    Blood; 2014 Nov; 124(23):3365-72. PubMed ID: 25428222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward optimal therapy for inhibitors in hemophilia.
    Kempton CL; Meeks SL
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):364-71. PubMed ID: 25696880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key issues in inhibitor management in patients with haemophilia.
    Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of factor VIII inhibitors: evolution and current status.
    Bloom AL
    Haemostasis; 1992; 22(5):268-75. PubMed ID: 1478538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
    Franchini M; Coppola A; Tagliaferri A; Lippi G
    Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hemophilia patients with inhibitors.
    Hedner U; Glazer S
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1035-46. PubMed ID: 1400071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.
    Leissinger CA
    Am J Hematol; 2004 Oct; 77(2):187-93. PubMed ID: 15389908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibitors in haemophilia A: current management and open issues.
    Haya S; Moret A; Cid AR; Cortina V; Casaña P; Cabrera N; Aznar JA
    Haemophilia; 2007 Dec; 13 Suppl 5():52-60. PubMed ID: 18078398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I manage patients with inherited haemophilia A and B and factor inhibitors.
    Ljung RCR
    Br J Haematol; 2018 Feb; 180(4):501-510. PubMed ID: 29270992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.
    Ljung R; Auerswald G; Benson G; Dolan G; Duffy A; Hermans C; Jiménez-Yuste V; Lambert T; Morfini M; Zupančić-Šalek S; Santagostino E
    Eur J Haematol; 2019 Feb; 102(2):111-122. PubMed ID: 30411401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors.
    López-Fernández MF; Altisent Roca C; Álvarez-Román MT; Canaro Hirnyk MI; Mingot-Castellano ME; Jiménez-Yuste V; Cid Haro AR; Pérez-Garrido R; Sedano Balbas C
    Thromb Haemost; 2016 May; 115(5):872-95. PubMed ID: 26842562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerance induction in hemophilia: innovation and accomplishments.
    Sherman A; Biswas M; Herzog RW
    Curr Opin Hematol; 2018 Sep; 25(5):365-372. PubMed ID: 29994897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allergy and inhibitors in hemophilia - a rare complication with potential novel solutions.
    Levy-Mendelovich S; Livnat T; Barg AA; Kidon M; Brutman-Barazani T; Kenet G
    Blood Cells Mol Dis; 2020 Feb; 80():102370. PubMed ID: 31669933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches in the management of inhibitor patients.
    Young G
    Acta Haematol; 2006; 115(3-4):172-9. PubMed ID: 16549892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.